Cerecin appoints veteran Singaporean Pharmaceutical Executive, Cheryl Tan, as Head of Commercial Strategy

Tan will lead the positioning of Cerecin's pipeline of highly innovative neurotherapeutics

SINGAPORE,Oct. 24,2018 -- Brain health-focused pharmaceutical company Cerecin,today announced the appointment of Cheryl Tan as Vice President,Commercial and Partnering. Ms Tan is based in Cerecin's global headquarters in Singapore.

Cerecin today announced the appointment of Cheryl Tan as Vice President,Commercial and Partnering.

Ms Tan has over 20 years' experience in commercialization of pharmaceutical and medical nutrition products and has held senior management positions in several leading pharmaceutical companies. She joins Cerecin's senior management team from Sanofi Genzyme,where she was previously Head of Hematology and Pediatrics for Emerging Markets (Asia,MENA,Latin America) and Head of Marketing for Asia. At Cerecin,she will lead the commercial strategy for the pipeline of innovative drugs that are in development and the commercialization of Axona® in the Asia Pacific region. Axona® is a medical food intended for the dietary management of the metabolic processes associated with Alzheimer's disease.

Prior to Sanofi Genzyme,Ms Tan worked for Actelion Pharmaceuticals,where she was instrumental in establishing and driving the growth of Actelion specialty portfolio in Asia. She has also worked in Abbott Laboratories in various divisions-- Pharmaceuticals,Medical Nutrition and Hospitals. Prior to her role at Abbott,she held regional positions in Allergan,Becton Dickinson,Novartis and GSK. She has an honours degree in Pharmacy,a MBA from the London School of Economics. She has also attended executive training programs with INSEAD,HARVARD and IMD. She was on the Board of Directors of the Singapore Association of Pharmaceutical Industries,and currently serves as Board member of Pearl Care.

Commenting on her appointment,Cheryl said,"I am excited to be joining Cerecin's executive team and be part of the growing team headquartered in Singapore. Neurology,particularly neurodegenerative disease,is a huge area of unmet medical need. Cerecin's strategy to address novel targets with differentiated compounds is cutting edge. I look forward to leveraging my experience in different therapeutic areas,geographies and products categories to help Cerecin develop therapeutics that will impact millions of lives."

Charles Stacey,President and CEO of Cerecin,said,"We are very pleased to have Cheryl join our team and spearhead the commercial strategy for Cerecin. We believe it is critically important for innovative companies like ours to have strong commercial guidance and input into all of our programmes. Cheryl's career has demonstrated her commercial acumen,broad and entrepreneurial expertise in medical marketing and strong network. Cheryl will help us ensure that our innovative products are developed,and ultimately positioned,to have maximum impact on patients and families across the world."

About Cerecin

Cerecin,previously Accera,is a global healthcare company focused on developing brain health solutions and therapeutics for patients around the world. Cerecin is led by an expert executive management team with globally recognized specialists in central nervous system diseases and supported by two partners,Nestlé and Wilmar International. Cerecin's lead compound,tricaprilin,is intended to address the metabolic deficit that is known to be characteristic of Alzheimer's disease by providing the brain with an alternative energy substrate. Cerecin is currently preparing this newly reformulated compound for global pivotal studies. Bringing together the deep industry expertise of its leadership team and the extensive market access capabilities of its strategic investors,Cerecin is growing its global presence to build a brighter future for Alzheimer's patients.

For more information visit www.cerecin.com.

About Axona®

Axona is a medical food that is intended to address glucose hypometabolism in the Alzheimer's brain. It is designed to address the cerebral hypometabolism that occurs decades before the diagnosis of Alzheimer's disease. Axona has been on the market in the United States since 2009. Last year,Cerecin announced the first regional Asian license agreement signed with Korean pharmaceutical company,DuChemBio.

For more information,visit http://www.cerecin.com/axona.html.

© 2018 Cerecin AC-18-837 10/18

Photo - /20181023/2276473-1